Tuberculosis and HIV co-infection in three patients: The possibilities for simultaneous treatment;Tuberculose- en HIV-co-infectie bij 3 patiënten: Mogelijkheden voor gelijktijdige behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 9, 2003, Pages 369-372

  Van Oosterhout, J J G ^a   Boeree, M J ^a   Burger, D M ^a   De Lange, W C M ^a   Van Crevel, R ^a,b   Koopmans, P P ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; MALE; PATIENT COMPLIANCE; PNEUMOCYSTIS CARINII; SIDE EFFECT; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TUBERCULOSIS;

EID: 0037336157     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA, Maher D, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001;357:15-23.
2. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS 1997;11:S115-23.
3. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999;340:367-73.
4. Horsburgh CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000;31:633-9.
5. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12.
6. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001;120:193-7.
7. Orlovic D, Smego jr RA. Paradoxical tuberculous reactions in HIV infected patients. Int J Tuberc Lung Dis 2004;4:370-5.
8. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
9. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve-infected adults; a randomized equivalence trial. JAMA 2001;285:1155-63.
10. Veldkamp AI, Hoetelmans RMW, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampicin and saquinavir. Clin Infect Dis 1999;29:1586.
11. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41:681-90.
12. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000;30:779-83.
13. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampicin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000;49:185-9.
14. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001;28:450-3.
15. Burger DM, Aarnoutse RE, Hugen PWH. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002;15:17-22.
16. DeSimone JA, Pomerantz RJ, Babinchak U. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54.
17. Cinti SK, Armstrong WS, Kauffman CA. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 2001;44:497-501.
18. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, Ann Intern Med 2000;133:21-30.
19. Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-8.
20. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 2):S171-6.
21. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al, Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16:75-83.